SGMT (Sagimet Biosciences, Inc.) Earnings per share for the last four quarters

Sagimet Biosciences (SGMT) is building biochemical supply chains through a diversified network of laboratories, which protects business profitability. Historical price action, where EPS TTM stands at 33.70, correlates with the use of AI in molecular discovery and the automation of drug synthesis. Growth prospects are based on the denifanstat patent, which provides access to the high-margin metabolic steatohepatitis therapy segment.
SGMT (Sagimet Biosciences): analytical breakdowns and indicator data

The investment attractiveness of Sagimet Biosciences (SGMT) is driven by its success in treating metabolic liver pathologies and the scientific expertise of its management. This metric measures the annual dynamics of net income per share over twelve months, capturing the business's actual growth rate. Analyzing the rolling annual change in EPS allows investors to filter out market noise and identify overvaluation risks. The stability of this trend confirms the fundamental value of the company's capital.